<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="pmc-domain-id">2657</journal-id><journal-id journal-id-type="pmc-domain">frontmedicine</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10450509</article-id><article-id pub-id-type="pmcid-ver">PMC10450509.1</article-id><article-id pub-id-type="pmcaid">10450509</article-id><article-id pub-id-type="pmcaiid">10450509</article-id><article-id pub-id-type="pmid">37636579</article-id><article-id pub-id-type="doi">10.3389/fmed.2023.1218051</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Associations between smoke exposure and kidney stones: results from the NHANES (2007&#8211;2018) and Mendelian randomization analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/2306567/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="H">Hexi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="C">Chengwei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="F">Fulin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="H">Huiyi</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/2304101/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Urology, The First Affiliated Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Api Chewcharat, Massachusetts General Hospital and Harvard Medical School, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Giovanni Motterle, Azienda ULSS 6 Euganea, Italy; Giuseppe Reitano, University Hospital of Padua, Italy</p></fn><corresp id="c001">*Correspondence: Yao Zhang <email>zhangyao7407@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">427505</issue-id><elocation-id>1218051</elocation-id><history><date date-type="received"><day>09</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-28 11:25:25.120"><day>28</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Huang, Wang, Xu, Zhou, Su and Zhang.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Huang, Wang, Xu, Zhou, Su and Zhang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmed-10-1218051.pdf"/><abstract><sec><title>Purpose</title><p>It is currently controversial whether smoke exposure is associated with the risk of kidney stones. Herein, publicly available databases were combined to explore relationships with the risk of nephrolithiasis in terms of smoking status and serum cotinine concentrations.</p></sec><sec><title>Materials and methods</title><p>First, we conducted an observational study using data from 2007 to 2018, based on the National Health and Nutrition Examination Survey (NHANES) database. Univariate analysis, multivariate logistic regression, trend testing, restricted cubic spline (RCS), and multiple imputation (MI) were the main analytical methods of our study. Then, A Mendelian randomization (MR) analysis was performed to explore the causal relationship between serum cotinine and nephrolithiasis. Genetic instruments for serum cotinine and pooled data for kidney stones were derived from publicly available large-scale genome-wide association studies (GWAS). Inverse-variance weighting (IVW) was the primary method for our MR analysis.</p></sec><sec><title>Results</title><p>A total of 34,657 and 31,352 participants were included in the observational study based on smoking status and serum cotinine concentrations, respectively. Under full adjustment of covariates, current smokers had an increased risk of kidney stones compared to non-smokers [OR = 1.17 (1.04&#8211;1.31), <italic toggle="yes">P</italic> = 0.009, P for trend = 0.010]. Compared with serum cotinine of &lt;0.05 ng/ml, serum cotinine levels of 0.05&#8211;2.99 ng/ml [OR = 1.15 (1.03&#8211;1.29), <italic toggle="yes">P</italic> = 0.013] and &#8805;3.00 ng/ml [OR = 1.22 (1.10&#8211;1.37), <italic toggle="yes">P</italic> &lt; 0.001] were observed to have a higher risk of nephrolithiasis (<italic toggle="yes">P</italic> for trend &lt; 0.001). In addition, a non-linear relationship between log2-transformed serum cotinine and the risk of nephrolithiasis was found (<italic toggle="yes">P</italic> for non-linearity = 0.028). Similar results were found when serum cotinine (log<sub>2</sub> transformation) was used as a continuous variable [OR = 1.02 (1.01&#8211;1.03), <italic toggle="yes">P</italic> &lt; 0.001] or complete data was used to analyze after MI. In the MR analysis, genetically predicted high serum cotinine was causally related to the high risk of nephrolithiasis [IVW: OR = 1.09 (1.00&#8211;1.19), <italic toggle="yes">P</italic> = 0.044].</p></sec><sec><title>Conclusion</title><p>Current smoking and high serum cotinine concentrations may be associated with an increased risk of kidney stones. Further research is needed to validate this relationship and explore its underlying mechanisms.</p></sec></abstract><kwd-group><kwd>smoking status</kwd><kwd>serum cotinine</kwd><kwd>kidney stone</kwd><kwd>NHANES</kwd><kwd>Mendelian randomization</kwd></kwd-group><counts><fig-count count="5"/><table-count count="3"/><equation-count count="0"/><ref-count count="44"/><page-count count="12"/><word-count count="7106"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Nephrology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Kidney stones are a common urinary disorder characterized by the deposition of minerals that are free or attached to the renal papilla located in the renal pelvis or calyces (<xref rid="B1" ref-type="bibr">1</xref>). According to epidemiology surveys of kidney stones and published articles, the incidence and prevalence of kidney stones are increasing annually (<xref rid="B2" ref-type="bibr">2</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>), which are influenced by many factors, such as sociodemographics, lifestyle habits, diseases, diet, and medications (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Early prevention of kidney stones can reduce the socioeconomic burden they cause (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Therefore, it makes sense to know the modifiable risk factors for kidney stones so that clinicians can better assist patients in preventing and treating kidney stones.</p><p>Previous studies have shown that smoke exposure is strongly associated with the risk of impaired health, including an increased risk of kidney stones (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). One systematic review explored the relationship between lifestyle and nephrolithiasis, namely smoking, alcohol consumption, and exercise. The findings suggest a significant association between smoking and kidney stone formation, but further research is needed due to a lack of sufficient data (<xref rid="B11" ref-type="bibr">11</xref>). Cotinine, the most important primary metabolite of nicotine, is a biomarker of tobacco exposure, and its concentrations in the body are closely related to tobacco consumption (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>).</p><p>Nevertheless, there are few clinical studies discussing the association between smoke exposure and the risk of kidney stones. In this study, we explore the relationship between smoking status and kidney stone formation in terms of participants' smoking status and serum cotinine concentrations based on the National Health and Nutrition Examination Survey (NHANES). Mendelian randomization (MR) is a method of analysis through instrumental variables. It uses single nucleotide polymorphisms (SNPs) in genome-wide association studies (GWAS) as study objects to detect causality between exposure (e.g., serum cotinine) and outcome (e.g., kidney stone). Compared to observational studies, MR is not affected by confounding factors or reverse causation. Generally, our study combined the NHANES study and MR analysis to analyze the association between smoke exposure and the risk of nephrolithiasis, which would make the results more reliable.</p></sec><sec id="s2"><title>2. Materials and methods</title><sec><title>2.1. The study population in NHANES</title><p>The NHANES is a population-based cross-sectional survey designed to assess health and nutritional status within the US population (<xref rid="B14" ref-type="bibr">14</xref>). Since 1999, approximately 5,000 nationally representative individuals have been surveyed annually, and related data have been published biennially. Demographics, methodology, examination data, dietary data, questionnaire data, and laboratory data were included in the survey; specific information could be found on the website <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nhanes" ext-link-type="uri">https://www.cdc.gov/nchs/nhanes</ext-link>. The National Center for Health Statistics (NCHS) Ethics Review Board approved the NHANES study protocol. In this study, data for six periods were included, from 2007 to 2018, in our collection. This period received attention because data on kidney stones became available in 2007 and the coronavirus disease 2019 (COVID-19) had not yet become epidemic in 2018. We explored the relationship between smoke exposure and kidney stones in terms of participants' smoking status and serum cotinine concentrations. The following were the exclusion criteria for this study: (1) missing/without data about kidney stones (<italic toggle="yes">n</italic> = 25,163); (2) missing/without data about smoking status (<italic toggle="yes">n</italic> = 22); and (3) missing/without data about serum cotinine concentrations in a population with a complete kidney stone and smoking status data (<italic toggle="yes">n</italic> = 3,305). Questionnaires on kidney stones were conducted only for those older than 20 years. Therefore, the population included in this study was all adults. In terms of smoking status, 34,657 participants out of 59,842 participants were screened in our study population. On the other hand, in terms of serum cotinine concentrations, a total of 31,352 participants were included. <xref rid="F1" ref-type="fig">Figure 1</xref> shows details of the inclusion and exclusion processes for this study.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of sample selection from NHANES (2007&#8211;2018).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmed-10-1218051-g0001.jpg"/></fig></sec><sec><title>2.2. Assessment of smoke exposure and kidney stones in NHANES</title><p>For the definition of smoking status, all participants needed to answer this question first, &#8220;In your lifetime, have you smoked more than 100 cigarettes?&#8221; Those who answered &#8220;No&#8221; were labeled as &#8220;Non-smokers,&#8221; while those who answered &#8220;Yes&#8221; were required to answer the following question further: &#8220;Do you smoke now?&#8221; The person who answered &#8220;Some days&#8221; or &#8220;Every day&#8221; was labeled as a &#8220;Current smoker,&#8221; and those who answered &#8220;Not at all&#8221; were labeled as &#8220;Former smokers.&#8221; In general, participants were divided into &#8220;non-smokers,&#8221; &#8220;former smokers,&#8221; and &#8220;current smokers.&#8221;</p><p>Cotinine, a major nicotine biomarker, was the first choice for assessing smoke exposure by measuring cotinine concentrations in blood, urine, and saliva (<xref rid="B15" ref-type="bibr">15</xref>). Compared with other diagnostic tools, cotinine was the best indicator of tobacco use because of its high sensitivity, good specificity, and long half-life (<xref rid="B16" ref-type="bibr">16</xref>). The liquid chromatography/atmospheric pressure ionization tandem mass spectrometric method was used to measure serum cotinine concentrations (<xref rid="B17" ref-type="bibr">17</xref>). Based on previous studies (<xref rid="B18" ref-type="bibr">18</xref>&#8211;<xref rid="B20" ref-type="bibr">20</xref>), we used 0.05 and 3.00 ng/ml as cutoff values to further convert serum cotinine concentrations into categorical variables. The class of serum cotinine was embodied in &lt;0.05 ng/ml, 0.05&#8211;2.99 ng/ml, and &#8805;3.00 ng/ml. In addition, a log<sub>2</sub> transformation was used for serum cotinine because of its skewed distribution, and then it was analyzed as a continuous variable.</p><p>Participants answered the question &#8220;Have you ever had kidney stones?&#8221; in the kidney condition questionnaire, and those who answered &#8220;Yes&#8221; were identified as having a clear history of kidney stones (<xref rid="B4" ref-type="bibr">4</xref>).</p></sec><sec><title>2.3. Covariate definition in NHANES</title><p>Through previously published studies, we screened factors associated with smoke exposure, cotinine, or kidney stones. These included age, sex, race, marital status, education, income-to-poverty ratio in the family (family PIR), body mass index (BMI), physical activity, serum uric acid, hypertension, coronary heart disease, diabetes, and gout (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B21" ref-type="bibr">21</xref>&#8211;<xref rid="B25" ref-type="bibr">25</xref>). Continuous variables included age, family PIR, BMI, and serum uric acid. Categorical variables included sex, race, marital status, education, physical activity, hypertension, coronary heart disease, diabetes, and gout. Vigorous or moderate work for at least 10 min continuously was labeled as an active physical activity. Hypertension was established when one of the following three conditions was present: systolic blood pressure &#8805;140 mmHg, diastolic blood pressure &#8805;90 mmHg or being on antihypertensive medications. Fasting blood glucose &#8805;126 mg/dl or glycohemoglobin &#8805;6.5% was labeled as diabetes. With or without coronary heart disease and gout were divided by answering the corresponding questionnaire &#8220;Yes&#8221; or &#8220;No.&#8221;</p></sec><sec><title>2.4. Genetically instrumental variables for serum cotinine in MR</title><p>We used a genome-wide association study to obtain genetic instrumental variables for serum cotinine, which involved 5,185 current smokers (serum cotinine &gt;10 ng/ml) of European ancestry (<xref rid="B26" ref-type="bibr">26</xref>). We screened the SNPs using the following steps, which were also the basic conditions of MR analysis: first, SNPs closely related to serum cotinine were screened out with a threshold <italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;6</sup>. Then, under the parameters, <italic toggle="yes">r</italic><sup>2</sup> &lt;0.001 and kb = 10,000, SNPs with linkage disequilibrium (LD) were removed. Finally, the <italic toggle="yes">F</italic> statistic was calculated for each SNP. Those <italic toggle="yes">F</italic> statistics &gt;10 were considered strong instrumental variables (<xref rid="B27" ref-type="bibr">27</xref>) and strongly associated with serum cotinine. The flowchart of MR is shown in <xref rid="F2" ref-type="fig">Figure 2</xref>. In addition, the three core assumptions about MR are shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Flowchart of Mendelian Randomization analysis. MR, Mendelian randomization; GWAS, genome-wide association study; MR-PRESSO, MR-Pleiotropy RESidual Sum and Outlier; IVW, inverse-variance weighting; MR-RAPS, MR-robust adjusted profile score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmed-10-1218051-g0002.jpg"/></fig></sec><sec><title>2.5. Genetic summary data on kidney stones in MR</title><p>GWAS summary data on kidney stones were available in the FinnGen consortium (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://finngen.gitbook.io/documentation/" ext-link-type="uri">https://finngen.gitbook.io/documentation/</ext-link>), which was a growing project among the Finns. We used the Release 6 (R6) version of data on kidney stones, which included 5,985 cases and 253,943 controls.</p></sec><sec><title>2.6. Statistical analyses</title><p>Complex sampling designs need to be considered to make our study population nationally representative. During the analysis, we used the sample weights from the NHANES database. By stratifying smoking status and serum cotinine concentrations, the weighted baseline characteristics of the overall population and participants under the corresponding stratification were described. Categorical variables and continuous variables were represented by percentages and the mean &#177; standard deviation (SD), weighted chi-square test, and weighted linear regression model were used to calculate the <italic toggle="yes">P</italic>-value, respectively. When analyzing serum cotinine concentrations as a continuous variable, a log<sub>2</sub> transformation was implemented to meet a normal distribution. In addition, the variance inflation factor (VIF) was calculated to avoid the existence of multicollinearity, and a VIF of &lt;10 could be considered to indicate that there was no multicollinearity between covariates (<xref rid="B28" ref-type="bibr">28</xref>). Univariate analysis was performed on participants based on smoking status and serum cotinine to judge the association between covariates and kidney stones. Then, three multivariate logistic regression models were constructed to explore the relationship between smoke exposure and kidney stones. Age, sex, race, and BMI were adjusted in Model 1. Model 2 adjusted marital status, education, family PIR, and physical activity based on Model 1. Model 3 adjusted serum uric acid, hypertension, coronary heart disease, diabetes, and gout based on Model 2. Based on Model 3 adjustments, a possible non-linear relationship was explored by constructing a restricted cubic spline (RCS) between serum cotinine (log<sub>2</sub> transformation) and the risk of kidney stones. The number of knots in RCS was set to 5 because of the large sample size, and the serum cotinine concentration with OR = 1 was set as the reference value. In addition, to avoid bias in the results caused by too many missing values, the multiple imputation (MI) method, which was done <italic toggle="yes">via</italic> the &#8220;MICE&#8221; package in R software (<xref rid="B29" ref-type="bibr">29</xref>), was used to supplement the missing values and verify the robustness of the results. Five complete sets of data were obtained through MI, and finally, the effect values of the five datasets were integrated. Model 4 represented the effect values integrated after MI based on the fully adjusted model.</p><p>In this MR analysis, we used inverse-variance weighting (IVW) as our main research method. The presence or absence of heterogeneity determined whether a random-effects model or a fixed-effects model was used in the analysis. In addition, we used the MR-Egger, the weighted mode, and the weighted median for sensitivity analysis. Previous studies had described the details of these methods (<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>). The MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method was used to rule out outliers and test for horizontal pleiotropy. Furthermore, directional pleiotropy was determined by the MR-Egger intercept method. Heterogeneity was detected by the Cochrane Q test. MR-robust adjusted profile score (MR-RAPS) could correct pleiotropy with adjusted file scoring and make our results more reliable when many weak instrumental variables existed (<xref rid="B31" ref-type="bibr">31</xref>). Eventually, if the potential effects of SNPs were found in the &#8220;leave-one-out&#8221; analysis, then we needed to draw conclusions with caution (<xref rid="B27" ref-type="bibr">27</xref>). A scatter plot was created to visually observe the association between serum cotinine and the risk of nephrolithiasis.</p><p>All statistical analyses were performed using R Software (Version 4.2.1, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.R-project.org" ext-link-type="uri">http://www.R-project.org</ext-link>, The R Foundation) and Empowerstats Software (Version 2.0, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.empowerstats.com" ext-link-type="uri">http://www.empowerstats.com</ext-link>, X&amp;Y Solutions, Inc., Boston, MA). In our study, a <italic toggle="yes">p</italic>-value of &lt;0.05 was considered statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><sec><title>3.1. Baseline characteristics of the study participants in NHANES</title><p>In the aspect of smoking status, the weighted baseline characteristics of the study population are shown in <xref rid="T1" ref-type="table">Table 1</xref>. Non-smokers, former smokers, and current smokers consisted of 19,414 (56.02%), 8,219 (23.72%), and 7,024 (20.27%) participants, respectively. We found statistically significant differences in age, sex, race, marital status, education level, family PIR, BMI, physical activity, history of hypertension, history of coronary heart disease, history of diabetes, history of gout, and history of kidney stones in different smoking status groups (all <italic toggle="yes">P</italic>-values &lt;0.001). The average age of the overall participants was 47.48 &#177; 17.02 (mean &#177; SD) years. The majority of the study population was female (51.91%) and non-Hispanic white (65.89%). Compared to the other groups, the current group of smokers was younger, had a lower family PIR, had lower serum uric acid, had a lower BMI, had active physical activity, and had no history of hypertension, coronary heart disease, diabetes, or gout. In particular, the population had a high prevalence of kidney stones (9.72%).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Weighted baseline characteristics of participants with smoking status (<italic toggle="yes">n</italic> = 34,657).</p></caption><table frame="box" rules="all"><thead><tr style="background-color:#919498;color:#ffffff"><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Characteristics</bold>
</th><th valign="top" align="center" colspan="4" rowspan="1">
<bold>Smoking status</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic>-value</bold>
</th></tr></thead><tbody><tr style="background-color:#919498;color:#ffffff"><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Non-smokers</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Former smokers</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Current smokers</bold>
</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="center" rowspan="1" colspan="1">34,657</td><td valign="top" align="center" rowspan="1" colspan="1">19,414</td><td valign="top" align="center" rowspan="1" colspan="1">8,219</td><td valign="top" align="center" rowspan="1" colspan="1">7,024</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Kidney stone (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">90.19</td><td valign="top" align="center" rowspan="1" colspan="1">91.13</td><td valign="top" align="center" rowspan="1" colspan="1">87.97</td><td valign="top" align="center" rowspan="1" colspan="1">90.28</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">9.81</td><td valign="top" align="center" rowspan="1" colspan="1">8.87</td><td valign="top" align="center" rowspan="1" colspan="1">12.03</td><td valign="top" align="center" rowspan="1" colspan="1">9.72</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Sociodemographic variables</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">47.48 &#177; 17.02</td><td valign="top" align="center" rowspan="1" colspan="1">46.02 &#177; 17.10</td><td valign="top" align="center" rowspan="1" colspan="1">54.37 &#177; 16.61</td><td valign="top" align="center" rowspan="1" colspan="1">43.13 &#177; 14.66</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family PIR (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">2.98 &#177; 1.66</td><td valign="top" align="center" rowspan="1" colspan="1">3.14 &#177; 1.65</td><td valign="top" align="center" rowspan="1" colspan="1">3.17 &#177; 1.59</td><td valign="top" align="center" rowspan="1" colspan="1">2.28 &#177; 1.58</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Sex (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">48.09</td><td valign="top" align="center" rowspan="1" colspan="1">41.80</td><td valign="top" align="center" rowspan="1" colspan="1">57.56</td><td valign="top" align="center" rowspan="1" colspan="1">54.23</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">51.91</td><td valign="top" align="center" rowspan="1" colspan="1">58.20</td><td valign="top" align="center" rowspan="1" colspan="1">42.44</td><td valign="top" align="center" rowspan="1" colspan="1">45.77</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Race (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mexican American</td><td valign="top" align="center" rowspan="1" colspan="1">8.58</td><td valign="top" align="center" rowspan="1" colspan="1">9.96</td><td valign="top" align="center" rowspan="1" colspan="1">6.78</td><td valign="top" align="center" rowspan="1" colspan="1">6.91</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-Hispanic Black</td><td valign="top" align="center" rowspan="1" colspan="1">11.40</td><td valign="top" align="center" rowspan="1" colspan="1">12.22</td><td valign="top" align="center" rowspan="1" colspan="1">7.15</td><td valign="top" align="center" rowspan="1" colspan="1">14.32</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-Hispanic White</td><td valign="top" align="center" rowspan="1" colspan="1">65.89</td><td valign="top" align="center" rowspan="1" colspan="1">61.41</td><td valign="top" align="center" rowspan="1" colspan="1">75.56</td><td valign="top" align="center" rowspan="1" colspan="1">66.66</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="center" rowspan="1" colspan="1">14.13</td><td valign="top" align="center" rowspan="1" colspan="1">16.41</td><td valign="top" align="center" rowspan="1" colspan="1">10.51</td><td valign="top" align="center" rowspan="1" colspan="1">12.11</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Education (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High school graduate or less</td><td valign="top" align="center" rowspan="1" colspan="1">39.11</td><td valign="top" align="center" rowspan="1" colspan="1">33.15</td><td valign="top" align="center" rowspan="1" colspan="1">39.63</td><td valign="top" align="center" rowspan="1" colspan="1">55.35</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Some college or AA</td><td valign="top" align="center" rowspan="1" colspan="1">31.25</td><td valign="top" align="center" rowspan="1" colspan="1">30.15</td><td valign="top" align="center" rowspan="1" colspan="1">32.52</td><td valign="top" align="center" rowspan="1" colspan="1">32.79</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">College graduate or above</td><td valign="top" align="center" rowspan="1" colspan="1">29.64</td><td valign="top" align="center" rowspan="1" colspan="1">36.70</td><td valign="top" align="center" rowspan="1" colspan="1">27.86</td><td valign="top" align="center" rowspan="1" colspan="1">11.86</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Marital status (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cohabitation</td><td valign="top" align="center" rowspan="1" colspan="1">37.13</td><td valign="top" align="center" rowspan="1" colspan="1">35.92</td><td valign="top" align="center" rowspan="1" colspan="1">32.65</td><td valign="top" align="center" rowspan="1" colspan="1">46.12</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Live alone</td><td valign="top" align="center" rowspan="1" colspan="1">62.87</td><td valign="top" align="center" rowspan="1" colspan="1">64.08</td><td valign="top" align="center" rowspan="1" colspan="1">67.35</td><td valign="top" align="center" rowspan="1" colspan="1">53.88</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Laboratory data variables</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serum uric acid, mg/dl (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">5.42 &#177; 1.42</td><td valign="top" align="center" rowspan="1" colspan="1">5.32 &#177; 1.40</td><td valign="top" align="center" rowspan="1" colspan="1">5.68 &#177; 1.45</td><td valign="top" align="center" rowspan="1" colspan="1">5.38 &#177; 1.39</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Physical examination and personal life</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">29.08 &#177; 6.92</td><td valign="top" align="center" rowspan="1" colspan="1">29.08 &#177; 6.99</td><td valign="top" align="center" rowspan="1" colspan="1">29.81 &#177; 6.75</td><td valign="top" align="center" rowspan="1" colspan="1">28.18 &#177; 6.80</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Physical activity (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Active</td><td valign="top" align="center" rowspan="1" colspan="1">44.91</td><td valign="top" align="center" rowspan="1" colspan="1">41.59</td><td valign="top" align="center" rowspan="1" colspan="1">46.26</td><td valign="top" align="center" rowspan="1" colspan="1">52.65</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inactive</td><td valign="top" align="center" rowspan="1" colspan="1">55.09</td><td valign="top" align="center" rowspan="1" colspan="1">58.41</td><td valign="top" align="center" rowspan="1" colspan="1">53.74</td><td valign="top" align="center" rowspan="1" colspan="1">47.35</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Hypertension (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">65.73</td><td valign="top" align="center" rowspan="1" colspan="1">68.78</td><td valign="top" align="center" rowspan="1" colspan="1">54.75</td><td valign="top" align="center" rowspan="1" colspan="1">70.84</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">34.27</td><td valign="top" align="center" rowspan="1" colspan="1">31.22</td><td valign="top" align="center" rowspan="1" colspan="1">45.25</td><td valign="top" align="center" rowspan="1" colspan="1">29.16</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Diabetes (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">89.56</td><td valign="top" align="center" rowspan="1" colspan="1">90.79</td><td valign="top" align="center" rowspan="1" colspan="1">85.34</td><td valign="top" align="center" rowspan="1" colspan="1">91.32</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">10.44</td><td valign="top" align="center" rowspan="1" colspan="1">9.21</td><td valign="top" align="center" rowspan="1" colspan="1">14.66</td><td valign="top" align="center" rowspan="1" colspan="1">8.68</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Coronary heart disease (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">96.54</td><td valign="top" align="center" rowspan="1" colspan="1">97.68</td><td valign="top" align="center" rowspan="1" colspan="1">93.79</td><td valign="top" align="center" rowspan="1" colspan="1">96.72</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">3.46</td><td valign="top" align="center" rowspan="1" colspan="1">2.32</td><td valign="top" align="center" rowspan="1" colspan="1">6.21</td><td valign="top" align="center" rowspan="1" colspan="1">3.28</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Gout (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">95.93</td><td valign="top" align="center" rowspan="1" colspan="1">96.84</td><td valign="top" align="center" rowspan="1" colspan="1">92.96</td><td valign="top" align="center" rowspan="1" colspan="1">97.03</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">4.07</td><td valign="top" align="center" rowspan="1" colspan="1">3.16</td><td valign="top" align="center" rowspan="1" colspan="1">7.04</td><td valign="top" align="center" rowspan="1" colspan="1">2.97</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>As for grouping according to serum cotinine concentrations, the weighted baseline characteristics are shown in <xref rid="T2" ref-type="table">Table 2</xref>: 16,650 (53.11%), 6,426 (20.50%), and 8,276 (49.71%) participants in the group with serum cotinine of &lt;0.05 ng/ml, 0.05&#8211;2.99 ng/ml, and &#8805;3.00 ng/ml, respectively. The average age of the overall participants was 47.57 &#177; 16.94 (mean &#177; SD) years. We did not observe a statistically significant difference in whether participants had a history of coronary heart disease (<italic toggle="yes">P</italic>-value = 0.176) or kidney stones (<italic toggle="yes">P</italic>-value = 0.067). The remaining characteristics in the serum cotinine &#8805;3.00 ng/ml group were similar to those of the participants in the current smoker group. Similarly, a high prevalence of kidney stones (10.19%) in participants with serum cotinine concentrations of &#8805;3.00 ng/ml was discovered.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Weighted baseline characteristics of participants with serum cotinine concentrations (<italic toggle="yes">n</italic> = 31,352).</p></caption><table frame="box" rules="all"><thead><tr style="background-color:#919498;color:#ffffff"><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Characteristics</bold>
</th><th valign="top" align="center" colspan="4" rowspan="1">
<bold>Serum cotinine concentrations</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">P</italic>-value</bold>
</th></tr></thead><tbody><tr style="background-color:#919498;color:#ffffff"><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;<bold>0.05 ng/ml</bold></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.05&#8211;2.99 ng/ml</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#8805;<bold>3.00 ng/ml</bold></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of participants</td><td valign="top" align="center" rowspan="1" colspan="1">31,352</td><td valign="top" align="center" rowspan="1" colspan="1">16,650</td><td valign="top" align="center" rowspan="1" colspan="1">6,426</td><td valign="top" align="center" rowspan="1" colspan="1">8,276</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Kidney stone (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.0672</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">90.08</td><td valign="top" align="center" rowspan="1" colspan="1">90.41</td><td valign="top" align="center" rowspan="1" colspan="1">89.45</td><td valign="top" align="center" rowspan="1" colspan="1">89.81</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">9.92</td><td valign="top" align="center" rowspan="1" colspan="1">9.59</td><td valign="top" align="center" rowspan="1" colspan="1">10.55</td><td valign="top" align="center" rowspan="1" colspan="1">10.19</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Sociodemographic variables</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">47.57 &#177; 16.94</td><td valign="top" align="center" rowspan="1" colspan="1">50.45 &#177; 16.97</td><td valign="top" align="center" rowspan="1" colspan="1">45.19 &#177; 17.59</td><td valign="top" align="center" rowspan="1" colspan="1">43.14 &#177; 15.10</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Family PIR (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">2.99 &#177; 1.65</td><td valign="top" align="center" rowspan="1" colspan="1">3.37 &#177; 1.58</td><td valign="top" align="center" rowspan="1" colspan="1">2.68 &#177; 1.63</td><td valign="top" align="center" rowspan="1" colspan="1">2.41 &#177; 1.61</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Sex (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">48.21</td><td valign="top" align="center" rowspan="1" colspan="1">43.12</td><td valign="top" align="center" rowspan="1" colspan="1">48.70</td><td valign="top" align="center" rowspan="1" colspan="1">58.68</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">51.79</td><td valign="top" align="center" rowspan="1" colspan="1">56.88</td><td valign="top" align="center" rowspan="1" colspan="1">51.30</td><td valign="top" align="center" rowspan="1" colspan="1">41.32</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Race (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mexican American</td><td valign="top" align="center" rowspan="1" colspan="1">8.66</td><td valign="top" align="center" rowspan="1" colspan="1">9.98</td><td valign="top" align="center" rowspan="1" colspan="1">8.46</td><td valign="top" align="center" rowspan="1" colspan="1">6.03</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-Hispanic black</td><td valign="top" align="center" rowspan="1" colspan="1">10.76</td><td valign="top" align="center" rowspan="1" colspan="1">6.93</td><td valign="top" align="center" rowspan="1" colspan="1">15.93</td><td valign="top" align="center" rowspan="1" colspan="1">15.24</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-Hispanic white</td><td valign="top" align="center" rowspan="1" colspan="1">66.51</td><td valign="top" align="center" rowspan="1" colspan="1">68.20</td><td valign="top" align="center" rowspan="1" colspan="1">60.33</td><td valign="top" align="center" rowspan="1" colspan="1">67.33</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other</td><td valign="top" align="center" rowspan="1" colspan="1">14.06</td><td valign="top" align="center" rowspan="1" colspan="1">14.90</td><td valign="top" align="center" rowspan="1" colspan="1">15.28</td><td valign="top" align="center" rowspan="1" colspan="1">11.40</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Education (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High school graduate or less</td><td valign="top" align="center" rowspan="1" colspan="1">38.82</td><td valign="top" align="center" rowspan="1" colspan="1">29.74</td><td valign="top" align="center" rowspan="1" colspan="1">44.96</td><td valign="top" align="center" rowspan="1" colspan="1">53.75</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Some college or AA</td><td valign="top" align="center" rowspan="1" colspan="1">31.38</td><td valign="top" align="center" rowspan="1" colspan="1">29.38</td><td valign="top" align="center" rowspan="1" colspan="1">34.68</td><td valign="top" align="center" rowspan="1" colspan="1">33.28</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">College graduate or above</td><td valign="top" align="center" rowspan="1" colspan="1">29.80</td><td valign="top" align="center" rowspan="1" colspan="1">40.88</td><td valign="top" align="center" rowspan="1" colspan="1">20.36</td><td valign="top" align="center" rowspan="1" colspan="1">12.97</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Marital status (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cohabitation</td><td valign="top" align="center" rowspan="1" colspan="1">36.55</td><td valign="top" align="center" rowspan="1" colspan="1">30.01</td><td valign="top" align="center" rowspan="1" colspan="1">43.90</td><td valign="top" align="center" rowspan="1" colspan="1">45.21</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Live alone</td><td valign="top" align="center" rowspan="1" colspan="1">63.45</td><td valign="top" align="center" rowspan="1" colspan="1">69.99</td><td valign="top" align="center" rowspan="1" colspan="1">56.10</td><td valign="top" align="center" rowspan="1" colspan="1">54.79</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Laboratory data variables</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serum uric acid, mg/dl (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">5.42 &#177; 1.42</td><td valign="top" align="center" rowspan="1" colspan="1">5.32 &#177; 1.39</td><td valign="top" align="center" rowspan="1" colspan="1">5.61 &#177; 1.47</td><td valign="top" align="center" rowspan="1" colspan="1">5.48 &#177; 1.42</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Physical examination and personal life</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup> (mean &#177; SD)</td><td valign="top" align="center" rowspan="1" colspan="1">29.09 &#177; 6.89</td><td valign="top" align="center" rowspan="1" colspan="1">29.01 &#177; 6.57</td><td valign="top" align="center" rowspan="1" colspan="1">30.17 &#177; 7.65</td><td valign="top" align="center" rowspan="1" colspan="1">28.48 &#177; 6.88</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Physical activity (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Active</td><td valign="top" align="center" rowspan="1" colspan="1">45.33</td><td valign="top" align="center" rowspan="1" colspan="1">41.48</td><td valign="top" align="center" rowspan="1" colspan="1">46.09</td><td valign="top" align="center" rowspan="1" colspan="1">52.94</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inactive</td><td valign="top" align="center" rowspan="1" colspan="1">54.67</td><td valign="top" align="center" rowspan="1" colspan="1">58.52</td><td valign="top" align="center" rowspan="1" colspan="1">53.91</td><td valign="top" align="center" rowspan="1" colspan="1">47.06</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Hypertension (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">65.89</td><td valign="top" align="center" rowspan="1" colspan="1">63.78</td><td valign="top" align="center" rowspan="1" colspan="1">65.44</td><td valign="top" align="center" rowspan="1" colspan="1">70.71</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">34.11</td><td valign="top" align="center" rowspan="1" colspan="1">36.22</td><td valign="top" align="center" rowspan="1" colspan="1">34.56</td><td valign="top" align="center" rowspan="1" colspan="1">29.29</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Diabetes (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.0016</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">89.59</td><td valign="top" align="center" rowspan="1" colspan="1">89.35</td><td valign="top" align="center" rowspan="1" colspan="1">88.91</td><td valign="top" align="center" rowspan="1" colspan="1">90.60</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">10.41</td><td valign="top" align="center" rowspan="1" colspan="1">10.65</td><td valign="top" align="center" rowspan="1" colspan="1">11.09</td><td valign="top" align="center" rowspan="1" colspan="1">9.40</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Coronary heart disease (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.1763</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">96.52</td><td valign="top" align="center" rowspan="1" colspan="1">96.35</td><td valign="top" align="center" rowspan="1" colspan="1">96.81</td><td valign="top" align="center" rowspan="1" colspan="1">96.68</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">3.48</td><td valign="top" align="center" rowspan="1" colspan="1">3.65</td><td valign="top" align="center" rowspan="1" colspan="1">3.19</td><td valign="top" align="center" rowspan="1" colspan="1">3.32</td><td rowspan="1" colspan="1"/></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Gout (%)</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.0392</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">95.94</td><td valign="top" align="center" rowspan="1" colspan="1">95.92</td><td valign="top" align="center" rowspan="1" colspan="1">95.47</td><td valign="top" align="center" rowspan="1" colspan="1">96.33</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">4.06</td><td valign="top" align="center" rowspan="1" colspan="1">4.08</td><td valign="top" align="center" rowspan="1" colspan="1">4.53</td><td valign="top" align="center" rowspan="1" colspan="1">3.67</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec><title>3.2. Univariate analysis of kidney stones based on smoking status and serum cotinine concentrations in NHANES</title><p>The correlation between covariates and kidney stones based on smoking status is shown in <xref rid="SM3" ref-type="supplementary-material">Supplementary Table S1</xref>. Among participants with or without a history of kidney stones, we found that age, sex, race, marital status, BMI, education level, and serum uric acid were statistically significant (<italic toggle="yes">P</italic> &lt; 0.001). On the other hand, hypertension, coronary heart disease, diabetes, and gout were closely related to the occurrence of kidney stones. The above features were also observed in participants based on serum cotinine concentrations, which are demonstrated in <xref rid="SM4" ref-type="supplementary-material">Supplementary Table S2</xref>.</p></sec><sec><title>3.3. Associations of smoking status and serum cotinine concentrations with the risk of kidney stones in NHANES</title><p>The association between smoking status and kidney stones is presented in <xref rid="T3" ref-type="table">Table 3</xref>. We found that the current smoker group was strongly associated with the occurrence of kidney stones compared to the non-smoker group regardless of the adjustment model [Model 1: OR = 1.19 (1.07&#8211;1.32), <italic toggle="yes">P</italic> &lt; 0.001; Model 2: OR = 1.18 (1.05&#8211;1.31), <italic toggle="yes">P</italic> = 0.004; Model 3: OR = 1.17 (1.04&#8211;1.31), <italic toggle="yes">P</italic> = 0.009], while these features were not observed in former smokers (all <italic toggle="yes">P</italic> &gt; 0.05). Similar results were obtained in former smokers (<italic toggle="yes">P</italic> = 0.249) and current smokers [OR = 1.16 (1.05&#8211;1.28), <italic toggle="yes">P</italic> = 0.005] in Model 4. Therefore, current smokers have a higher risk of developing kidney stones (<italic toggle="yes">P</italic> for trend in Model 1, Model 2, and Model 3: &lt;0.001, 0.004, and 0.010, respectively).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Association between smoking status, serum cotinine concentrations, and risk of kidney stones.</p></caption><table frame="box" rules="all"><thead><tr style="background-color:#919498;color:#ffffff"><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Exposure</bold>
</th><th valign="top" align="center" colspan="4" rowspan="1"><bold>OR (95% CI)</bold>, <italic toggle="yes"><bold>P</bold></italic></th></tr></thead><tbody><tr style="background-color:#919498;color:#ffffff"><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Model 1</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Model 2</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Model 3</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>Model 4</bold>
</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Smoking status, category</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Non-smokers</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Former smokers</td><td valign="top" align="center" rowspan="1" colspan="1">1.08 (0.99, 1.18), 0.095</td><td valign="top" align="center" rowspan="1" colspan="1">1.07 (0.97, 1.18), 0.182</td><td valign="top" align="center" rowspan="1" colspan="1">1.06 (0.96, 1.17), 0.288</td><td valign="top" align="center" rowspan="1" colspan="1">1.05 (0.96, 1.15), 0.249</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Current smokers</td><td valign="top" align="center" rowspan="1" colspan="1">1.19 (1.07, 1.32), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.18 (1.05, 1.31), 0.004</td><td valign="top" align="center" rowspan="1" colspan="1">1.17 (1.04, 1.31), 0.009</td><td valign="top" align="center" rowspan="1" colspan="1">1.16 (1.05, 1.28), 0.005</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td><td valign="top" align="center" rowspan="1" colspan="1">0.010</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Serum cotinine concentrations</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Log<sub>2</sub>-transformed serum cotinine (ng/ml)</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (1.01, 1.03), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (1.01, 1.03), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (1.01, 1.03), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (1.01, 1.03), &lt;0.001</td></tr><tr style="background-color:#dee1e1"><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Cotinine level, category</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.05 ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td><td valign="top" align="center" rowspan="1" colspan="1">Ref</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">0.05&#8211;2.99 ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">1.16 (1.04, 1.28), 0.005</td><td valign="top" align="center" rowspan="1" colspan="1">1.16 (1.04, 1.30), 0.006</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (1.03, 1.29), 0.013</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (1.04, 1.28), 0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8805;3.00 ng/ml</td><td valign="top" align="center" rowspan="1" colspan="1">1.25 (1.14, 1.38), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.25 (1.12, 1.39), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.22 (1.10, 1.37), &lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">1.23 (1.11, 1.36), &lt;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> for trend</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><p>Model 1 adjusted age, sex, race, and BMI; Model 2 adjusted for Model 1 plus marital status, education, family PIR, and physical activity; Model 3 adjusted for Model 2 plus serum uric acid, hypertension, coronary heart disease, diabetes, and gout; Model 4 represented the effect values integrated after MI based on Model 3.</p></table-wrap-foot></table-wrap><p><xref rid="T3" ref-type="table">Table 3</xref> shows the association between serum cotinine as a continuous or categorical variable and the occurrence of nephrolithiasis. Log2-transformed serum cotinine was linked with an increased risk of kidney stones [the effect values were the same for either model: OR = 1.02 (1.01&#8211;1.03), <italic toggle="yes">P</italic> &lt; 0.001]. No matter which adjustment model they were under, those with serum cotinine of 0.05&#8211;2.99 ng/ml and &#8805; 3.00 ng/ml had varying degrees of increased risk of developing kidney stones compared with the control group (serum cotinine &lt;0.05 ng/ml), especially in participants with higher serum cotinine concentrations [&#8805;3.00 ng/ml; Model 1: OR = 1.25 (1.14&#8211;1.38, <italic toggle="yes">P</italic> &lt; 0.001; Model 2: OR = 1.25 (1.12&#8211;1.39), <italic toggle="yes">P</italic> &lt; 0.001; Model 3: OR = 1.22 (1.10&#8211;1.37), <italic toggle="yes">P</italic> &lt; 0.001; Model 4: OR = 1.23 (1.11&#8211;1.36), <italic toggle="yes">P</italic> &lt; 0.001]. As the category of serum cotinine levels increased, the prevalence of kidney stones also increased (<italic toggle="yes">P</italic> for trend was all &lt;0.001 in Model 1, Model 2, and Model 3). Effect values for each of the five complete sets of data after MI, based on smoking status and serum cotinine concentrations, are presented in <xref rid="SM5" ref-type="supplementary-material">Supplementary Tables S3</xref>, <xref rid="SM6" ref-type="supplementary-material">S4</xref>, respectively.</p><p>In RCS, we observed a non-linear relationship between log2-transformed serum cotinine and kidney stone risk (<xref rid="F3" ref-type="fig">Figure 3</xref>; <italic toggle="yes">P</italic> for non-linearity = 0.028). The reference value is 5.206 ng/ml (serum cotinine = 36.91 ng/ml). When log<sub>2</sub>-transformed serum cotinine was below the reference value, the risk of kidney stones was little changed or even decreased, and when log<sub>2</sub>-transformed serum cotinine was above the reference value, the risk increased rapidly.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>Restricted cubic spline (RCS) analysis of log2-transformed serum cotinine and odds ratio of kidney stone disease based on Model 3. OR, odds ratio; CI, confidence interval; KSD, kidney stone disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmed-10-1218051-g0003.jpg"/></fig></sec><sec><title>3.4. A causal association between serum cotinine and kidney stones in MR</title><p>A total of 10 SNPs were eventually selected after a series of rigorous screenings, the details of which are shown in <xref rid="SM7" ref-type="supplementary-material">Supplementary Table S5</xref>. Genetically predicted serum cotinine was found to be associated with an increased risk of kidney stones by method IVW [<xref rid="F4" ref-type="fig">Figure 4</xref>; OR = 1.09 (1.00&#8211;1.19), <italic toggle="yes">P</italic> = 0.044] and MR-RAPS [OR = 1.10 (1.01&#8211;1.21), <italic toggle="yes">P</italic> = 0.038], but the MR-Egger, the weighted mode, and the weighted median did not find a causal relationship between the two. Furthermore, heterogeneity, directional pleiotropy, and horizontal pleiotropy were not observed in this study (see <xref rid="SM8" ref-type="supplementary-material">Supplementary Table S6</xref>). The results of MR analysis were influenced by potential SNPs, as could be seen by the &#8220;leave-one-out&#8221; plot, so conclusions needed to be drawn with caution (<xref rid="SM2" ref-type="supplementary-material">Supplementary Figure S2</xref>). The scatter plot showed that as serum cotinine levels increased, so did the risk of nephrolithiasis, which is demonstrated in <xref rid="F5" ref-type="fig">Figure 5</xref>.</p><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><p>Mendelian randomization analysis to explore the causal association between serum cotinine and kidney stones. Bold and red dots indicate that there is statistical significance (<italic toggle="yes">P</italic> &lt; 0.05). MR, Mendelian randomization; IVW-FE, inverse-variance weighting with fixed-effect model; MR-RAPS, MR-robust adjusted profile score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmed-10-1218051-g0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5</label><caption><p>Scatter plot for THE causal effect of serum cotinine on kidney stones. MR, Mendelian randomization; SNP, single nucleotide polymorphism; KSD, kidney stone disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmed-10-1218051-g0005.jpg"/></fig></sec></sec><sec id="s4"><title>4. Discussion</title><p>In this study, our results suggested smoke exposure as a risk factor for nephrolithiasis. The risk of kidney stones was increased in current smokers, which was found in our observational study. On the other hand, both the observational study and MR analysis supported a positive association between serum cotinine and the risk of nephrolithiasis. As far as we know, we were the first study to combine observational and MR studies to explore the relationship between smoke exposure and kidney stones.</p><p>A meta-analysis combining five observational studies published before 1 October 2021 showed a significant relationship between smoking and the risk of urolithiasis (<xref rid="B33" ref-type="bibr">33</xref>). In addition, later published research also found that both active and passive smoking may promote kidney stone formation (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). However, a cross-sectional study of southeastern Iran found a significant association between smoking and the risk of nephrolithiasis, but this link disappeared after adjusting for other variables (<xref rid="B34" ref-type="bibr">34</xref>). In addition, a retrospective epidemiological study showed that there was no reliable evidence that smoking was associated with the occurrence and recurrence of kidney stones (<xref rid="B35" ref-type="bibr">35</xref>). As the association between smoking and nephrolithiasis is currently controversial, this article aims to evaluate the link between the two with the help of a publicly available database.</p><p>In this article, the NHANES and the publicly available GWAS database were utilized to combine observational studies and MR analysis, which aimed to reveal whether smoke exposure could lead to an increased risk of kidney stone formation. The observational study, which analyzed participants' smoking status and serum cotinine concentrations, found a significant association between current smokers and a high risk of kidney stones that did not exist in former smokers. As the results of the questionnaire were easily influenced, we added a more objective indicator, serum cotinine, which could reflect the extent of an individual's exposure to smoking (<xref rid="B12" ref-type="bibr">12</xref>). Similarly, serum cotinine was linked with an increased risk of nephrolithiasis both as a continuous variable (log<sub>2</sub>-transformed) and as a categorical variable. The above results were stable regardless of the adjustment model. In the MR analysis, our results supported the association of high serum cotinine concentrations with an increased risk of nephrolithiasis by the IVW and MR-RAPS methods. Five MR methods were used to assess causality. IVW was our primary method, and at least two MR methods supported a causal relationship between exposure (e.g., serum cotinine) and outcome (e.g., kidney stones) so that the results could be considered robust (<xref rid="B36" ref-type="bibr">36</xref>). Our observational study was conducted in the US population, and the GWAS data on serum cotinine and kidney stones for MR analysis were all from European populations. This may suggest to some extent that smoke exposure may increase the incidence of nephrolithiasis in different populations.</p><p>The exact mechanism by which smoke exposure causes kidney stones is currently unclear, but there are several possible explanations. First, tobacco smoke contains many harmful substances, such as cadmium and lead, and studies have shown that cadmium and lead concentrations in kidney stones are associated with smoking (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Cadmium and lead exposure may increase the risk of kidney stones (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Second, smoking may lead to an increase in vasopressin levels, which has a strong vasoconstrictive effect, causing a decrease in urine output (<xref rid="B41" ref-type="bibr">41</xref>). Low urine output was a common risk for all types of stones (<xref rid="B21" ref-type="bibr">21</xref>). Third, cigarette smoking was an independent risk factor for calcium urolithiasis, and it could reduce urinary calcium excretion or promote calcium deposition in the kidneys through a variety of mechanisms (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Furthermore, smoking could release reactive oxygen species (ROS), which could cause kidney damage and accelerate the development of chronic kidney disease (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Renal tubular damage or dysfunction could promote the nucleation, aggregation, and retention of crystals in the kidneys, eventually leading to the development of kidney stones (<xref rid="B44" ref-type="bibr">44</xref>). Further research is needed to explore and discover the underlying mechanisms of kidney stones caused by smoke exposure.</p><p>There are some merits to our study. First, we guaranteed a sufficiently large sample size based on the NHANES database. Second, the use of the MI method compensated for the influence of missing values, making the results more robust. Third, the RCS was constructed to explore the existence of a non-linear relationship. More importantly, we combined observational study and MR analysis. A causal inference could not be drawn from the NHANES study alone. MR analysis could compensate for the shortcomings of observational studies, which are susceptible to reverse causation and confounding factors. In addition, large-scale GWAS data were used for the MR analysis, so that it had sufficient statistical power to evaluate the relationship between smoke exposure and kidney stones.</p><p>However, there were also some limitations to our study. In the observational study, the information about smoking status and kidney stones was measured through questionnaires, and the results were easily influenced. Next, the data on kidney stones did not provide specific types of stones, so stratified analysis cannot be performed to identify how smoke exposure is related to specific types of stones. In addition, metabolic changes in women pre- and post-menopause may contribute to changes in the risk of kidney stones. Since pre- and post-menopausal data were only available for certain time periods (NHANES 2005&#8211;2010), further research was needed to explore the effects of smoking status and serum cotinine on the risk of kidney stones in pre- and post-menopausal women. In the MR analysis, sensitivity analysis did not yield consistent results. The possible influence of potentially confounding SNPs could not be ruled out. Finally, our study population was American and European, which made our results regionally limited.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The results of an observational study suggest that current smoking may increase the risk of kidney stones. Combining the observational studies and MR analysis, we found that high serum cotinine concentrations increased the risk of nephrolithiasis and were causally associated with kidney stones. This result needs to be confirmed by further research, and the underlying mechanisms still need to be explored.</p></sec><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s10" ref-type="sec">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS) are responsible for conducting NHANES. All participants provided informed consent forms. The NHANES study protocol was approved by the NCHS Ethics Review Board. The GWAS data used in this study were derived from publicly published original studies that had received informed consent from participants and Ethics Committee approval at the time of publication.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>YH and YZ designed the research. YH conducted the formal analysis and wrote the original draft. HW and CX verified the data results. YH and HS made tables and figures. YH, HW, FZ, and HS edited and modified the article. YZ reviewed the final manuscript. All authors had read the final manuscript and endorsed its publication.</p></sec></body><back><ack><p>We thank all participants, staff, and institutions that have contributed to the NHANES database and the publicly available GWAS database.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr"><p>NHANES, National Health, and Nutrition Examination Survey; NCHS, National Center for Health Statistics; MR, Mendelian randomization; VIF, variance inflation factor; RCS, restricted cubic spline; MI, multiple imputation; GWAS, genome-wide association studies; SNPs, single nucleotide polymorphisms; IVW, inverse-variance weighting; KSD, kidney stone disease; BMI, body mass index; PIR, poverty&#8211;income ratio; COVID-19, coronavirus disease 2019; LD, linkage disequilibrium; MR-PRESSO, MR-Pleiotropy RESidual Sum and Outlier; MR-RAPS, MR-robust adjusted profile score; OR, odds ratio; CI, confidence interval; SD, standard deviation.</p></fn></fn-group><sec sec-type="COI-statement" id="conf1"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s9"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s10"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2023.1218051/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmed.2023.1218051/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Figure S1</label><caption><p>Three core assumptions about Mendelian randomization.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_1.PNG" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Figure S2</label><caption><p>&#8220;Leave-one-out&#8221; analysis plot of the causal relationship between serum cotinine and kidney stones.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Image_2.PNG" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S1</label><caption><p>Univariate analysis of kidney stones in the study population based on smoking status.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_1.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM4" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S2</label><caption><p>Univariate analysis of kidney stones in the study population based on serum cotinine concentrations.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_2.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM5" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S3</label><caption><p>The respective and pooled effect values after multiple imputation (MI) are based on smoking status.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_3.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM6" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S4</label><caption><p>The respective and pooled effect values after multiple imputations are based on serum cotinine concentrations.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_4.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM7" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S5</label><caption><p>Detailed information about screened-out SNPs.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_5.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM8" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Table S6</label><caption><p>Sensitivity analysis of the Mendelian randomization study.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table_6.DOCX" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>SR</given-names></name><name name-style="western"><surname>Pearle</surname><given-names>MS</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>WG</given-names></name><name name-style="western"><surname>Gambaro</surname><given-names>G</given-names></name><name name-style="western"><surname>Canales</surname><given-names>BK</given-names></name><name name-style="western"><surname>Doizi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Kidney stones</article-title>. <source>Nat Rev Dis Prim.</source> (<year>2016</year>) <volume>2</volume>:<fpage>16008</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.8</pub-id><pub-id pub-id-type="pmid">27188687</pub-id><pub-id pub-id-type="pmcid">PMC5685519</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scales</surname><given-names>CD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>AC</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Saigal</surname><given-names>CS</given-names></name><name name-style="western"><surname>Urologic Diseases in America</surname><given-names>Project</given-names></name></person-group>. <article-title>Prevalence of kidney stones in the United States</article-title>. <source>Eur Urol.</source> (<year>2012</year>) <volume>62</volume>:<fpage>160</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2012.03.052</pub-id><pub-id pub-id-type="pmid">22498635</pub-id><pub-id pub-id-type="pmcid">PMC3362665</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tundo</surname><given-names>G</given-names></name><name name-style="western"><surname>Vollstedt</surname><given-names>A</given-names></name><name name-style="western"><surname>Meeks</surname><given-names>W</given-names></name><name name-style="western"><surname>Pais</surname><given-names>V</given-names></name></person-group>. <article-title>Beyond prevalence: annual cumulative incidence of kidney stones in the United States</article-title>. <source>J Urol.</source> (<year>2021</year>) <volume>205</volume>:<fpage>1704</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/JU.0000000000001629</pub-id><pub-id pub-id-type="pmid">33502240</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Basourakos</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lewicki</surname><given-names>P</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Arenas-Gallo</surname><given-names>C</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Incidence of kidney stones in the United States: the continuous national health and nutrition examination survey</article-title>. <source>J Urol.</source> (<year>2022</year>) <volume>207</volume>:<fpage>851</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/JU.0000000000002331</pub-id><pub-id pub-id-type="pmid">34854755</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stamatelou</surname><given-names>K</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>DS</given-names></name></person-group>. <article-title>Epidemiology of kidney stones</article-title>. <source>Healthcare.</source> (<year>2023</year>) <volume>11</volume>:<fpage>424</fpage>. <pub-id pub-id-type="doi">10.3390/healthcare11030424</pub-id><pub-id pub-id-type="pmid">36766999</pub-id><pub-id pub-id-type="pmcid">PMC9914194</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chewcharat</surname><given-names>A</given-names></name><name name-style="western"><surname>Thongprayoon</surname><given-names>C</given-names></name><name name-style="western"><surname>Vaughan</surname><given-names>LE</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>RA</given-names></name><name name-style="western"><surname>Schulte</surname><given-names>PJ</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>HM</given-names></name><etal/></person-group>. <article-title>Dietary risk factors for incident and recurrent symptomatic kidney stones</article-title>. <source>Mayo Clinic Proc.</source> (<year>2022</year>) <volume>97</volume>:<fpage>1437</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.mayocp.2022.04.016</pub-id><pub-id pub-id-type="pmid">35933132</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geraghty</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cook</surname><given-names>P</given-names></name><name name-style="western"><surname>Walker</surname><given-names>V</given-names></name><name name-style="western"><surname>Somani</surname><given-names>BK</given-names></name></person-group>. <article-title>Evaluation of the economic burden of kidney stone disease in the UK: a retrospective cohort study with a mean follow-up of 19 years</article-title>. <source>BJU Int.</source> (<year>2020</year>) <volume>125</volume>:<fpage>586</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/bju.14991</pub-id><pub-id pub-id-type="pmid">31916369</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lotan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Buendia Jim&#233;nez</surname><given-names>I</given-names></name><name name-style="western"><surname>Lenoir-Wijnkoop</surname><given-names>I</given-names></name><name name-style="western"><surname>Daudon</surname><given-names>M</given-names></name><name name-style="western"><surname>Molinier</surname><given-names>L</given-names></name><name name-style="western"><surname>Tack</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Primary prevention of nephrolithiasis is cost-effective for a national healthcare system</article-title>. <source>BJU Int.</source> (<year>2012</year>) <volume>110</volume>:<fpage>E1060</fpage>&#8211;<lpage>1067</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11212.x</pub-id><pub-id pub-id-type="pmid">22686216</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamadon M</surname><given-names>R</given-names></name><name name-style="western"><surname>Nassaji</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>R</given-names></name></person-group>. <article-title>Cigarette smoking and nephrolitiasis in adult individuals</article-title>. <source>Nephrourol Mon.</source> (<year>2013</year>) <volume>5</volume>:<fpage>702</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5812/numonthly.5251</pub-id><pub-id pub-id-type="pmid">23577335</pub-id><pub-id pub-id-type="pmcid">PMC3614330</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J-I</given-names></name><name name-style="western"><surname>Jhan</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Geng</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-C</given-names></name><etal/></person-group>. <article-title>Secondhand smoke increases the risk of developing kidney stone disease</article-title>. <source>Sci Rep.</source> (<year>2021</year>) <volume>11</volume>:<fpage>17694</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-97254-y</pub-id><pub-id pub-id-type="pmid">34489505</pub-id><pub-id pub-id-type="pmcid">PMC8421344</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>P</given-names></name><name name-style="western"><surname>Karim Sulaiman</surname><given-names>S</given-names></name><name name-style="western"><surname>Gamage</surname><given-names>KN</given-names></name><name name-style="western"><surname>Tokas</surname><given-names>T</given-names></name><name name-style="western"><surname>Jamnadass</surname><given-names>E</given-names></name><name name-style="western"><surname>Somani</surname><given-names>BK</given-names></name></person-group>. <article-title>Do lifestyle factors including smoking, alcohol, and exercise impact your risk of developing kidney stone disease?</article-title><source>Outc System Rev J Endourol.</source> (<year>2021</year>) <volume>35</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1089/end.2020.0378</pub-id><pub-id pub-id-type="pmid">32808537</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names></name><name name-style="western"><surname>Benowitz N</surname><given-names>L</given-names></name></person-group>. <article-title>Metabolism and disposition kinetics of nicotine</article-title>. <source>Pharmacol Rev.</source> (<year>2005</year>) <volume>57</volume>:<fpage>79</fpage>&#8211;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1124/pr.57.1.3</pub-id><pub-id pub-id-type="pmid">15734728</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CM</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>SH</given-names></name><name name-style="western"><surname>Arab</surname><given-names>A</given-names></name><name name-style="western"><surname>Valle-Pinero</surname><given-names>AYD</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hatsukami</surname><given-names>DK</given-names></name></person-group>. <article-title>Biomarkers of tobacco exposure: summary of an FDA-sponsored public workshop</article-title>. <source>Cancer Epidemiol Biomar Prev.</source> (<year>2017</year>) <volume>26</volume>:<fpage>291</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0675</pub-id><pub-id pub-id-type="pmid">28151705</pub-id><pub-id pub-id-type="pmcid">PMC5336443</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name></person-group>. <article-title>Association between food insecurity and kidney stones in the United States: Analysis of the National Health and Nutrition Examination Survey 2007-2014</article-title>. <source>Front. Public Health.</source> (<year>2022</year>) <volume>10</volume>:<fpage>1015425</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2022.1015425</pub-id><pub-id pub-id-type="pmid">36438222</pub-id><pub-id pub-id-type="pmcid">PMC9682121</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>S</given-names></name><name name-style="western"><surname>Merino</surname><given-names>C</given-names></name><name name-style="western"><surname>Paton</surname><given-names>B</given-names></name><name name-style="western"><surname>Correig</surname><given-names>X</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>N</given-names></name></person-group>. <article-title>Biomarkers of exposure to secondhand and Thirdhand tobacco smoke: recent advances and future perspectives</article-title>. <source>Int J Environ Res Public Health.</source> (<year>2018</year>) <volume>15</volume>:<fpage>2693</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph15122693</pub-id><pub-id pub-id-type="pmid">30501044</pub-id><pub-id pub-id-type="pmcid">PMC6313747</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>M</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P</given-names></name><name name-style="western"><surname>Jha</surname><given-names>K</given-names></name><name name-style="western"><surname>Handa</surname><given-names>S</given-names></name></person-group>. <article-title>Diagnostic methods for detection of cotinine level in tobacco users: a review</article-title>. <source>J Clin Diagn Res.</source> (<year>2016</year>) <volume>10</volume>:<fpage>ZE04</fpage>&#8211;<lpage>06</lpage>. <pub-id pub-id-type="doi">10.7860/JCDR/2016/17360.7423</pub-id><pub-id pub-id-type="pmid">27135020</pub-id><pub-id pub-id-type="pmcid">PMC4843405</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernert</surname><given-names>JT</given-names></name><name name-style="western"><surname>Turner</surname><given-names>WE</given-names></name><name name-style="western"><surname>Pirkle</surname><given-names>JL</given-names></name><name name-style="western"><surname>Sosnoff</surname><given-names>CS</given-names></name><name name-style="western"><surname>Akins</surname><given-names>JR</given-names></name><name name-style="western"><surname>Waldrep</surname><given-names>MK</given-names></name><etal/></person-group>. <article-title>Development and validation of sensitive method for determination of serum cotinine in smokers and nonsmokers by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry</article-title>. <source>Clin Chem.</source> (<year>1997</year>) <volume>43</volume>:<fpage>2281</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1093/clinchem/43.12.2281</pub-id><pub-id pub-id-type="pmid">9439445</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Bernert</surname><given-names>JT</given-names></name><name name-style="western"><surname>Caraballo</surname><given-names>RS</given-names></name><name name-style="western"><surname>Holiday</surname><given-names>DB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group>. <article-title>Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004</article-title>. <source>Am J Epidemiol.</source> (<year>2009</year>) <volume>169</volume>:<fpage>236</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwn301</pub-id><pub-id pub-id-type="pmid">19019851</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Bernert</surname><given-names>JT</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>J</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>SS</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>P</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Biochemical verification of tobacco use and abstinence: 2019 update</article-title>. <source>Nicotine Tobacco Res.</source> (<year>2020</year>) <volume>22</volume>:<fpage>1086</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntz132</pub-id><pub-id pub-id-type="pmid">31570931</pub-id><pub-id pub-id-type="pmcid">PMC7882145</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name></person-group>. <article-title>Associations between smoke exposure and osteoporosis or osteopenia in a US NHANES population of elderly individuals</article-title>. <source>Front Endocrinol.</source> (<year>2023</year>) <volume>14</volume>:<fpage>1074574</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2023.1074574</pub-id><pub-id pub-id-type="pmid">36817605</pub-id><pub-id pub-id-type="pmcid">PMC9935577</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peerapen</surname><given-names>P</given-names></name><name name-style="western"><surname>Thongboonkerd</surname><given-names>V</given-names></name></person-group>. <article-title>Kidney stone prevention</article-title>. <source>Adv Nutr.</source> (<year>2023</year>) <volume>14</volume>:<fpage>555</fpage>&#8211;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.advnut.2023.03.002</pub-id><pub-id pub-id-type="pmid">36906146</pub-id><pub-id pub-id-type="pmcid">PMC10201681</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Intermediate effects of body mass index and c-reactive protein on the serum cotinine- leukocyte telomere length association</article-title>. <source>Front Aging Neurosci.</source> (<year>2021</year>) <volume>13</volume>:<fpage>827465</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.827465</pub-id><pub-id pub-id-type="pmid">35115918</pub-id><pub-id pub-id-type="pmcid">PMC8806079</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Association between physical activity and kidney stones based on dose-response analyses using restricted cubic splines</article-title>. <source>Eur J Public Health.</source> (<year>2020</year>) <volume>30</volume>:<fpage>1206</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/eurpub/ckaa162</pub-id><pub-id pub-id-type="pmid">32879977</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberg</surname><given-names>AE</given-names></name><name name-style="western"><surname>Patel</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chertow</surname><given-names>GM</given-names></name><name name-style="western"><surname>Leppert</surname><given-names>JT</given-names></name></person-group>. <article-title>Diabetic severity and risk of kidney stone disease</article-title>. <source>Eur Urol.</source> (<year>2014</year>) <volume>65</volume>:<fpage>242</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2013.03.026</pub-id><pub-id pub-id-type="pmid">23523538</pub-id><pub-id pub-id-type="pmcid">PMC3866968</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>B</given-names></name><name name-style="western"><surname>Luke</surname><given-names>A</given-names></name><name name-style="western"><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G</given-names></name><name name-style="western"><surname>Shoham</surname><given-names>D</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>H</given-names></name></person-group>. <article-title>Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994</article-title>. <source>Am J Kidney Dis.</source> (<year>2008</year>) <volume>51</volume>:<fpage>741</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2007.12.030</pub-id><pub-id pub-id-type="pmid">18436084</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchwald</surname><given-names>J</given-names></name><name name-style="western"><surname>Chenoweth</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Palviainen</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name><name name-style="western"><surname>Benner</surname><given-names>C</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent</article-title>. <source>Mol Psychiatry.</source> (<year>2021</year>) <volume>26</volume>:<fpage>2212</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-020-0702-z</pub-id><pub-id pub-id-type="pmid">32157176</pub-id><pub-id pub-id-type="pmcid">PMC7483250</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Z</given-names></name></person-group>. <article-title>Mendelian randomization study of inflammatory bowel disease and bone mineral density</article-title>. <source>BMC Med.</source> (<year>2020</year>) <volume>18</volume>:<fpage>312</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-020-01778-5</pub-id><pub-id pub-id-type="pmid">33167994</pub-id><pub-id pub-id-type="pmcid">PMC7654011</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mela</surname><given-names>CF</given-names></name><name name-style="western"><surname>Kopalle</surname><given-names>PK</given-names></name></person-group>. <article-title>The impact of collinearity on regression analysis: the asymmetric effect of negative and positive correlations</article-title>. <source>Appl Econ.</source> (<year>2002</year>) <volume>34</volume>:<fpage>667</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1080/00036840110058482</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>YS</given-names></name><name name-style="western"><surname>Gelman</surname><given-names>A</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J</given-names></name><name name-style="western"><surname>Yajima</surname><given-names>M</given-names></name></person-group>. <article-title>Multiple imputation with diagnostics (MI) in R: opening windows into the black box</article-title>. <source>J Stat Softw.</source> (<year>2011</year>) <volume>45</volume>:<fpage>1</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v045.i02</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Haycock</surname><given-names>PC</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group>. <article-title>Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator</article-title>. <source>Genet Epidemiol.</source> (<year>2016</year>) <volume>40</volume>:<fpage>304</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1002/gepi.21965</pub-id><pub-id pub-id-type="pmid">27061298</pub-id><pub-id pub-id-type="pmcid">PMC4849733</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartwig</surname><given-names>FP</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name></person-group>. <article-title>Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption</article-title>. <source>Int J Epidemiol.</source> (<year>2017</year>) <volume>46</volume>:<fpage>1985</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyx102</pub-id><pub-id pub-id-type="pmid">29040600</pub-id><pub-id pub-id-type="pmcid">PMC5837715</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Del Greco M</surname><given-names>F</given-names></name><name name-style="western"><surname>Minelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>NA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JR</given-names></name></person-group>. <article-title>Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic</article-title>. <source>Int J Epidemiol.</source> (<year>2016</year>) <volume>45</volume>:<fpage>1961</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyw220</pub-id><pub-id pub-id-type="pmid">27616674</pub-id><pub-id pub-id-type="pmcid">PMC5446088</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>L</given-names></name><name name-style="western"><surname>Pai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group>. <article-title>Smoking and risk of urolithiasis: meta-analysis of observational studies</article-title>. <source>Front. Public Health.</source> (<year>2022</year>) <volume>10</volume>:<fpage>816756</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2022.816756</pub-id><pub-id pub-id-type="pmid">35321192</pub-id><pub-id pub-id-type="pmcid">PMC8936389</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalili</surname><given-names>P</given-names></name><name name-style="western"><surname>Jamali</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>T</given-names></name><name name-style="western"><surname>Esmaeili-Nadimi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohamadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Moghadam-Ahmadi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Risk factors of kidney stone disease: a cross-sectional study in the southeast of Iran</article-title>. <source>BMC Urol.</source> (<year>2021</year>) <volume>21</volume>:<fpage>141</fpage>. <pub-id pub-id-type="doi">10.1186/s12894-021-00905-5</pub-id><pub-id pub-id-type="pmid">34625088</pub-id><pub-id pub-id-type="pmcid">PMC8499392</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detsyk</surname><given-names>O</given-names></name><name name-style="western"><surname>Solomchak</surname><given-names>D</given-names></name></person-group>. <article-title>The impact of cigarette smoking, alcohol drinking and physical inactivity on the risk of urolithiasis occurrence and recurrence</article-title>. <source>Wiadomosci Lekarskie.</source> (<year>2017</year>) <volume>70</volume>:<fpage>38</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="pmid">28343191</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>J-J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S-S</given-names></name><name name-style="western"><surname>Han</surname><given-names>B-X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X-T</given-names></name><etal/></person-group>. <article-title>Gut microbiota and psychiatric disorders: a two-sample Mendelian randomization study</article-title>. <source>Front Microbiol.</source> (<year>2021</year>) <volume>12</volume>:<fpage>737197</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.737197</pub-id><pub-id pub-id-type="pmid">35185808</pub-id><pub-id pub-id-type="pmcid">PMC8856606</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>RS</given-names></name></person-group>. <article-title>Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization</article-title>. <source>Metallomics.</source> (<year>2011</year>) <volume>3</volume>:<fpage>1181</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1039/c1mt00066g</pub-id><pub-id pub-id-type="pmid">21799956</pub-id><pub-id pub-id-type="pmcid">PMC4542087</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wermers</surname><given-names>M</given-names></name><name name-style="western"><surname>Pazdernik</surname><given-names>V</given-names></name><name name-style="western"><surname>Jannetto</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Bornhorst</surname><given-names>JA</given-names></name></person-group>. <article-title>Detection of cadmium and lead in kidney stones. Associations with patient demographics, stone composition, and smoking</article-title>. <source>J Appl Lab Med.</source> (<year>2023</year>) <volume>8</volume>:<fpage>330</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/jalm/jfac089</pub-id><pub-id pub-id-type="pmid">36575923</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name></person-group>. <article-title>Nephrotoxic metals of cadmium, lead, mercury and arsenic and the odds of kidney stones in adults: An exposure-response analysis of NHANES 2007-2016</article-title>. <source>Environ Int.</source> (<year>2019</year>) <volume>132</volume>:<fpage>105115</fpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2019.105115</pub-id><pub-id pub-id-type="pmid">31473411</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Z-Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z-Y</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G-Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H-L</given-names></name><name name-style="western"><surname>Aschner</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Association of lead and cadmium exposure with kidney stone incidence: A study on the non-occupational population in Nandan of China</article-title>. <source>J Trace Elements Med. Boil.</source> (<year>2021</year>) <volume>68</volume>:<fpage>126852</fpage>. <pub-id pub-id-type="doi">10.1016/j.jtemb.2021.126852</pub-id><pub-id pub-id-type="pmid">34508950</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooser</surname><given-names>V</given-names></name><name name-style="western"><surname>Burnier</surname><given-names>M</given-names></name><name name-style="western"><surname>Nussberger</surname><given-names>J</given-names></name><name name-style="western"><surname>Juillerat</surname><given-names>L</given-names></name><name name-style="western"><surname>Waeber</surname><given-names>B</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>HR</given-names></name></person-group>. <article-title>Effects of smoking and physical exercise on platelet free cytosolic calcium in healthy normotensive volunteers</article-title>. <source>J Hypertens.</source> (<year>1989</year>) <volume>7</volume>:<fpage>211</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00004872-198903000-00007</pub-id><pub-id pub-id-type="pmid">2708817</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaimes</surname><given-names>EA</given-names></name><name name-style="western"><surname>Tian</surname><given-names>RX</given-names></name><name name-style="western"><surname>Raij</surname><given-names>L</given-names></name></person-group>. <article-title>Nicotine: the link between cigarette smoking and the progression of renal injury?</article-title><source>Am J Physiol Heart Circ Physiol.</source> (<year>2007</year>) <volume>292</volume>:<fpage>H76</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00693.2006</pub-id><pub-id pub-id-type="pmid">16920799</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>C</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>EA</given-names></name></person-group>. <article-title>Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights</article-title>. <source>Curr Hypertens Rep.</source> (<year>2007</year>) <volume>9</volume>:<fpage>66</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s11906-007-0012-8</pub-id><pub-id pub-id-type="pmid">17362674</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>SR</given-names></name></person-group>. <article-title>Renal tubular damage/dysfunction: key to the formation of kidney stones</article-title>. <source>Urol Res.</source> (<year>2006</year>) <volume>34</volume>:<fpage>86</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s00240-005-0016-2</pub-id><pub-id pub-id-type="pmid">16404622</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>